Herceptin: Breast Cancer Drug Has Best Outcome When Used For One Year, Studies Show
Consensus forecasts from Thomson Reuters Pharma show analysts see T-DM1 generating sales of $918 million by 2016. (Editing
herceptin breast cancer drug good outcome year studies consensus forecast thomson reuters pharma analyst t dm generate sale  edit